Prescription Information Modernization Act of 2026
- Sponsor
- Sen. Banks, Jim [R-IN]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Aug 4, 2026
Bottom line
This bill modernizes the delivery of drug prescribing information by shifting to a digital-first approach while preserving access to paper copies upon request, aiming for efficiency and updated accessibility.
What it actually does
This bill amends the Federal Food, Drug, and Cosmetic Act to permit drug manufacturers to provide FDA-approved prescribing information for prescription drugs solely through electronic means. It mandates that manufacturers must still offer prescribers and dispensers the option to receive paper copies upon request, promptly and without additional cost. The bill also requires the Secretary of Health and Human Services to issue implementing regulations and hold a public workshop to optimize digital information formats.
Proponents argue
Supporters argue this bill will streamline the distribution of critical drug information, reduce waste associated with paper inserts, and ensure healthcare professionals have immediate access to the most up-to-date prescribing details digitally. It aligns with modern information delivery practices, can lower costs for manufacturers, and offers environmental benefits by reducing paper consumption.
Opponents contend
Critics might raise concerns about potential digital divides, especially for healthcare professionals in rural areas or those with limited internet access or technological proficiency, who might struggle to access digital-only information. There could also be concerns about ensuring the digital format is as comprehensive and easy to navigate as traditional paper inserts, and the potential burden of actively requesting paper copies.
The bill is very short and clear, making it highly accessible for any reader to understand its core provisions quickly.
Section 2(a) amending Section 502(f) of the Federal Food, Drug, and Cosmetic Act
Authorization for Electronic-Only Prescribing Information
This provision allows drug manufacturers to provide the required prescribing information for prescription drugs (including biologics) exclusively through electronic means. However, it mandates that manufacturers must still offer prescribers and dispensers the option to receive paper copies, either as a standing election or on an as-needed basis, and must provide these promptly and without additional cost upon request. This changes the default method of information delivery.
Supporters argue
Supporters argue this provision modernizes an outdated system, reduces environmental impact by cutting down on paper waste, and ensures healthcare providers can access the most current drug information more efficiently through digital platforms, which can be updated in real-time.
Critics contend
Opponents might argue that relying primarily on digital means could disadvantage healthcare providers with limited technological infrastructure or those who prefer physical copies for quick reference, potentially leading to delays or errors if digital access is not seamless or if the request process for paper copies is burdensome.
Tradeoffs
This provision balances the efficiency and environmental benefits of digital delivery against the need to ensure equitable and reliable access to critical information for all healthcare providers, including those who may prefer or require paper copies due to various circumstances.
Section 2(b) and 2(c)
Implementation Regulations and Stakeholder Engagement
This section requires the Secretary of Health and Human Services (HHS) to issue final regulations within one year to implement the digital communication changes and provide clear instructions for healthcare professionals to request paper copies. It also mandates that these regulations be designed to minimize adverse economic impacts on prescribers and dispensers. Furthermore, HHS, through the FDA Commissioner, must hold a public workshop within two years to discuss how to continue optimizing the format, accessibility, and usability of digital prescribing information.